58 Biggest Movers From Friday
Gainers
CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; CAI International Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 1.27% to 33,394.86 while the NASDAQ fell 0.92% to 14,031.05. The S&P also fell, dropping 1.03% to 4,178.31.
Mid-Day Market Update: Crude Oil Rises Over 1%; Orphazyme Shares Plunge
Midway through trading Friday, the Dow traded down 1.13% to 33,440.28 while the NASDAQ fell 0.74% to 14,056.31. The S&P also fell, dropping 0.92% to 4,183.07.
32 Stocks Moving In Friday’s Mid-Day Session
Gainers
CAI International, Inc. (NYSE: CAI) shares jumped 46.4% to $55.86 after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows.
Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings
Following the market opening Friday, the Dow traded down 1.25% to 33,401.59 while the NASDAQ fell 0.54% to 14,085.56. The S&P also fell, dropping 0.86% to 4,185.44.
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
28 Stocks Moving in Friday’s Pre-Market Session
Gainers
CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Athira Pharma Stock Plummets After CEO Placed On Temporary Leave
Athira Pharma Inc (NASDAQ:ATHA) CEO Leen Kawas has been placed on temporary leave until the company completes a review “stemming from…
Athira Pharma COO Mark Litton Assumes Day-To-Day Leadership Responsibilities Of Co
Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira"), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that